WallStreetZenWallStreetZen

NASDAQ: BCLI
Brainstorm Cell Therapeutics Inc Stock Ownership - Who owns Brainstorm Cell Therapeutics?

Insider buying vs selling

Have Brainstorm Cell Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Stacy LindborgCo-Chief Executive Officer2023-09-0111,500$1.77
$20.40kBuy

1 of 1

BCLI insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when BCLI insiders and whales buy or sell their stock.

BCLI Shareholders

What type of owners hold Brainstorm Cell Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Accbt Corp59.22%29,006,924$19.14MInsider
Chaim Lebovits5.31%2,599,340$1.72MInsider
Sankesh Abbhi4.44%2,175,853$1.44MInsider
Vanguard Group Inc2.91%1,423,310$939.38kInstitution
Blackrock Inc0.95%466,355$307.79kInstitution
Jonathan C. Javitt0.94%460,000$303.60kInsider
Stacy Lindborg0.86%423,435$279.47kInsider
Geode Capital Management LLC0.73%357,041$235.65kInstitution
Liberty Wealth Management LLC0.69%340,150$224.50kInstitution
Michael D. Greenfield0.61%300,000$198.00kInsider

1 of 3

BCLI vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
BCLI8.08%74.43%Net Buying
SRZN2.98%97.02%Net Buying
TCRT53.35%46.65%Net Selling
SPRB63.59%36.41%Net SellingNet Selling
CDIO8.07%35.97%Net BuyingNet Buying

Brainstorm Cell Therapeutics Stock Ownership FAQ

Who owns Brainstorm Cell Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ: BCLI) is owned by 8.08% institutional shareholders, 74.43% Brainstorm Cell Therapeutics insiders, and 17.49% retail investors. Accbt Corp is the largest individual Brainstorm Cell Therapeutics shareholder, owning 29.01M shares representing 59.22% of the company. Accbt Corp's Brainstorm Cell Therapeutics shares are currently valued at $17.40M.

If you're new to stock investing, here's how to buy Brainstorm Cell Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.